Insights

Dr Charabaty, from Johns Hopkins School of Medicine, discusses the poster presentation on the study of safety of ustekinumab among patients aged 60 years and older with inflammatory disease, which was shown at the recent American College of...

Dr Horst, from Vanderbilt University, reviews the results a study of how a delay of more than 14 days in escalating dosage of biologic treatment can affect outcomes for patients with IBD.

Dr Christina Ha, from Cedars-Sinai, moderated a discussion at the ACG Scientific Meeting with Dr Raymond Cross, from the University of Maryland, and Dr Bincy Abraham, from Houston Methodist, about beginning IBD therapy, changing therapeutic...

Dr Patil, from the University of Maryland School of Medicine, discusses the optimal and future uses of IL-12/23 inhibitors for the management of inflammatory bowel disease.

Dr Cheifetz, from Beth Israel Deaconess Medical Center in Boston, spoke about the treatment options available for patients with severe ulcerative colitis, from medical management to surgery at the recent Interdisciplinary Autoimmune Summit.

David Hudesman, MD, codirector of the IBD Center at NYU Langone Health, and Marla Dubinsky, MD, codirector of the Feinstein IBD Center at the Icahn School of Medicine at Mt Sinai, talk about the challenges of properly diagnosing and choosing...

Sunanda Kane, MD, from the Mayo Clinic and host Raymond Cross, MD, discuss JAK inhibitors in the treatment of inflammatory bowel disease in this IBD Drive Time.

In this podcast, Dr Edward Barnes discusses the highlights from his presentation on Immune Mediated Events Related To Medications from the Advances in Inflammatory Bowel Disease regional meeting September 25.

In this video Dr Regueiro, chair of the Digestive Disease and Surgery Institute at Cleveland Clinic, discusses his presentation on caring for the hospitalized patient with ulcerative colitis from the AIBD regional meeting on September 11.